Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Declines By 7.9%

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 132,900 shares, a decline of 7.9% from the November 15th total of 144,300 shares. Based on an average daily volume of 232,800 shares, the short-interest ratio is currently 0.6 days. Approximately 3.1% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets decreased their price objective on Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating for the company in a report on Monday.

Alzamend Neuro Stock Performance

Shares of NASDAQ:ALZN opened at $1.29 on Wednesday. The stock’s fifty day simple moving average is $1.44 and its two-hundred day simple moving average is $2.60. Alzamend Neuro has a 1-year low of $1.06 and a 1-year high of $15.06.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.